Maria Kalafateli

Dr. Maria Kalafateli


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KONSTANTINOS PAPANTONIOUKONSTANTINOS PAPANTONIOU
KONSTANTINOS PAPANTONIOU
Ioanna AggeletopoulouIoanna Aggeletopoulou
Ioanna Aggeletopoulou
MKMaria Kalafateli
Maria Kalafateli
Christos TriantosChristos Triantos
Christos Triantos
Background: Perivascular epithelioid cell tumors (PEComas) are a rare group of mesenchymal neoplasms with distinctive histological and immunohistochemical features. This systematic review aims to characterize the clinical presentation, diagnostic approach, treatment, and outcomes of adult patients with hepatic PEComa. Methods: We performed a systematic literature search for English-language articles regarding hepatic PEComas using the terms (perivascular epithelioid cell tumor) OR (PEComa) AND (liver) OR (hepatic), up to 25 May 2025. Results: A total of 145 studies encompassing 281 patients were included in the analysis. Most studies originated from Asia. The mean age at diagnosis was 46 years (IQR: 35.25–53.75) with a female predominance. The underlying comorbidities were uncommon among the reported cases, and more than half were asymptomatic at presentation. The tumor presented as a single liver lesion in almost 9 out of 10 patients. Surgical excision was the primary treatment, and diagnosis in 74% of patients was made with positive immunohistochemistry for markers such as HMB-45 and smooth muscle actin. A malignant phenotype was reported in 30 cases. The median follow-up duration was 24 months (IQR: 12–48); recurrence occurred in 17 patients, and disease-related mortality occurred in 8 patients. Conclusions: Primary hepatic PEComa is a rare liver tumor with mostly benign clinical behavior and non-specific presentation. Future studies are needed to support clinician decisions regarding this entity and improve patient care.

25 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
IGIoanna Maria Grypari
Ioanna Maria Grypari
DTDina Tiniakos
Dina Tiniakos
MKMaria Kalafateli
Maria Kalafateli
ETEleni Theocharidou
Eleni Theocharidou
Hepatocellular carcinoma (HCC) is the most common liver cancer and usually develops on a background of cirrhotic liver. Early and accurate diagnosis enables potentially curative interventions. HCC surveillance, usually offered to patients at risk for HCC, such as those with cirrhosis, chronic hepatitis B infection, and previous diagnosis of HCC, is associated with earlier detection and improved survival. In these patients, the diagnosis can be established non-invasively without histological confirmation when the imaging-based LI-RADS criteria are met. Tissue biopsy is mandatory for establishing diagnosis in patients without cirrhosis or other risk factors for HCC, differentiating HCC from other malignant and non-malignant entities, especially when imaging features are not conclusive. In this review, we discuss the evolving role of tissue biopsy beyond establishing the diagnosis, in providing important prognostic information and enabling precise histopathological classification. Features such as poor differentiation, microvascular invasion, and a pattern of vessels encapsulating tumor clusters are linked to worse prognosis. HCC is characterized by heterogeneity, with different histological subtypes associated with distinct clinical and radiological features and distinct biology. Emerging data from molecular profiling and immune-microenvironment studies enable further classification into proliferative versus non-proliferative molecular subgroups and inflamed versus non-inflamed immune subtypes. This more refined characterization of HCC carries important implications not only for prognostication but also for predicting response to immunotherapy. In the future, the combination of imaging features that correlate with molecular signatures, novel serum biomarkers, and liquid biopsy may provide less invasive tools for early detection, risk stratification, and guide personalized therapeutic strategies.